Scholarlink

<p>Although frequently used for anti-ulcerogenic and analgesic purposes, the <i>Monteverdia ilicifolia</i> (Mart. ex Reissek) Biral, popularly known as espinheira-santa, demonstrates scarcity of scientific evidence to confirm its efficacy. This study sought to answer the question "What is the scientific evidence on M<i>. ilicifolia</i> in relation to phytochemical, clinical, and technological development aspects?" by filling the information gaps regarding pre-clinical, clinical, and technological development perspectives through a scoping review involving articles and patents. Following the guidelines of the Joanna Briggs Institute and recommendations of PRISMA-ScR, the articles searches were carried out in the PubMed, Scopus, and Web of Science databases, while patents were searched on Google Patents, Espacenet, Derwent Innovations Index, and The Lens. All the studies found were checked for suitability to the topic. Approved studies went on a data extraction step, while the ones that did not fit the inclusion criteria had their exclusion reasoning recorded. 13 articles and three patents fitted the inclusion criteria and underwent data extraction. Studies showed that <i>M. ilicifolia</i> can be used in the form of aqueous, alcoholic, hydroalcoholic extracts, gels, creams, gel-creams, parenteral solutions, with doses of 0.1 to 500&#xa0;mg/kg, one to five times a day, and showed safety up to 3000&#xa0;mg/kg. Therapeutic properties included antimicrobial, antiulcer, spasmolytic, antidiarrheal, anti-inflammatory, natriuretic, diuretic, hypotensive and antimutagenic, with no observed toxicity or teratogenicity. Those effects were attributed to polyphenolic compounds, triterpenes, tannins, flavonoids, gallic and caffeic acids, exhibiting a variety of modes of action. Espinheira-santa shown promising evidence about its biological activities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Espinheira-santa phytochemical, pharmacological, and technological aspects: a scoping review

  • 期刊论文

  • 发表日期：

    2025年4月8日

查看全文
  • Ahmad Kassem El Zein,
  • Joel Toribio Espinoza,
  • Lazo Raul Edison Luna,
  • Jane Manfron,
  • Luana Mota Ferreira,
  • Roberto Pontarolo

摘要

Although frequently used for anti-ulcerogenic and analgesic purposes, the Monteverdia ilicifolia (Mart. ex Reissek) Biral, popularly known as espinheira-santa, demonstrates scarcity of scientific evidence to confirm its efficacy. This study sought to answer the question "What is the scientific evidence on M. ilicifolia in relation to phytochemical, clinical, and technological development aspects?" by filling the information gaps regarding pre-clinical, clinical, and technological development perspectives through a scoping review involving articles and patents. Following the guidelines of the Joanna Briggs Institute and recommendations of PRISMA-ScR, the articles searches were carried out in the PubMed, Scopus, and Web of Science databases, while patents were searched on Google Patents, Espacenet, Derwent Innovations Index, and The Lens. All the studies found were checked for suitability to the topic. Approved studies went on a data extraction step, while the ones that did not fit the inclusion criteria had their exclusion reasoning recorded. 13 articles and three patents fitted the inclusion criteria and underwent data extraction. Studies showed that M. ilicifolia can be used in the form of aqueous, alcoholic, hydroalcoholic extracts, gels, creams, gel-creams, parenteral solutions, with doses of 0.1 to 500 mg/kg, one to five times a day, and showed safety up to 3000 mg/kg. Therapeutic properties included antimicrobial, antiulcer, spasmolytic, antidiarrheal, anti-inflammatory, natriuretic, diuretic, hypotensive and antimutagenic, with no observed toxicity or teratogenicity. Those effects were attributed to polyphenolic compounds, triterpenes, tannins, flavonoids, gallic and caffeic acids, exhibiting a variety of modes of action. Espinheira-santa shown promising evidence about its biological activities.